ArticleRespiratory research2012
Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice.
Article in Respiratory research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2014Trial
- Fluticasone Propionate/Anti-IgE Combination Preserves Bone Mechanical and Mineral Integrity Better than Monotherapies or Anti-TNF-α in Mice with Ovalbumin-Induced Allergic Airway Inflammation.International journal of molecular sciences · 2026Article
- Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Observational
- Severe aspiration pneumonia in the elderly.Journal of intensive medicine · 2024Review
- Applying Next-Generation Sequencing and Multi-Omics in Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2023Review
- Article
- Effects of Fluticasone Propionate onmSphere · 2022Article
- Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.Antimicrobial agents and chemotherapy · 2022Article
- Inhaled Corticosteroids and the Lung Microbiome in COPD.Biomedicines · 2021Review
- Pneumonia prevention in the elderly patients: the other sides.Aging clinical and experimental research · 2021Article
- Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease.Pathogens (Basel, Switzerland) · 2021Review
- Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.Science translational medicine · 2019Article
- Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection.Annals of the American Thoracic Society · 2018Article
- Lung Macrophage Phenotypes and Functional Responses: Role in the Pathogenesis of COPD.International journal of molecular sciences · 2018Review
- Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.Lung · 2017Article
- Diphenyldifluoroketone EF24 Suppresses Pro-inflammatory Interleukin-1 receptor 1 and Toll-like Receptor 4 in lipopolysaccharide-stimulated dendritic cells.Journal of inflammation (London, England) · 2015Article
- Does roflumilast induce phagocytic activity in COPD patients?International journal of chronic obstructive pulmonary disease · 2015Article
- Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis.The Lancet. Respiratory medicine · 2014Article
- Article
- Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.International journal of chronic obstructive pulmonary disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent trials demonstrate increased pneumonia risk in chronic obstructive pulmonary disease patients treated with the inhaled corticosteroid (ICS) fluticasone propionate (FP). There is limited work describing FP effects on host defenses against bacterial pneumonia.
methodsC57BL/6 mice received daily, nose-only exposure to nebulized FP or vehicle for 8 days, followed by pulmonary challenge with Klebsiella pneumoniae. Bacterial burden, phagocytosis, leukocyte recruitment, cytokine expression, nitric oxide release, and survival were measured.
resultsInhaled FP increased bacterial burden in lungs and blood 48 h after infection but affected neither in vivo phagocytosis of bacteria by alveolar macrophages (AM) nor alveolar neutrophil recruitment. AM from FP-treated mice showed impaired expression of infection induced TNF-alpha, IP-10 (CXCL-10), and interleukin 6 (IL-6), and AM also showed a trend towards impaired intracellular pathogen control following in vivo infection. In vitro FP treatment resulted in a dose-dependent impairment of cytokine expression by AM. Furthermore, infection-induced nitric oxide (but not hydrogen peroxide) production was impaired by FP in vivo and in vitro. FP decreased survival in this model.
conclusionsExposure to inhaled FP impairs pulmonary clearance of K. pneumoniae in mice, an effect associated with greater systemic bacteremia and death. Decreased AM cytokine and nitric oxide expression parallel the failure to control infection. These results support the study of ICS effects on human pulmonary host defenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.